血清miRNA-135、miRNA-141与PSA对前列腺癌的诊断及预后的研究进展  

Research Progress of Serum miRNA-135, miRNA-141 and PSA in the Diagnosis and Prognosis of Prostate Cancer

作　　者：李江帆 郑宝寿 刘晨一男 

机构地区：[1]大理大学第一附属医院泌尿外科,云南 大理

出　　处：《临床医学进展》2024年第8期229-239,共11页Advances in Clinical Medicine

摘　　要：前列腺癌是老年男性的常见恶性肿瘤,我国患者在治疗时多属于中晚期,总体预后不佳。如何提高疾病早期诊断率,是其治疗关键。目前PSA和直肠指诊是前列腺癌筛查的主要手段,而如何在前列腺特异性抗原(prostate specific antigen, PSA)灰区时,提高诊断的灵敏度和特异性及避免不必要的前列腺穿刺活检是目前研究的热点。近年的实验研究中,发现了一些蛋白质标志物、分子标志物和微小RNA (microRNA, miRNA)等。且研究也证实了这些指标可以提高前列腺癌诊断灵敏度和准确性,本文将对此类国内外关于血清miRNA-135、miRNA-141与PSA对前列腺癌的诊断及预后的研究情况进行综述。Prostate cancer is a common malignant tumor in elderly men. Most patients in our country are in the middle and late stages of treatment, and the overall prognosis is poor. How to improve the early diagnosis rate of the disease is the key to its treatment. At present, PSA and digital rectal examination are the main means of prostate cancer screening, and how to improve the sensitivity and specificity of diagnosis and avoid unnecessary prostate biopsy in the gray area of prostate specific antigen (PSA) is a current research hotspot. In recent years, some protein markers, molecular markers and microRNA (microRNA, miRNA) have been discovered in experimental studies. And studies have also confirmed that these indicators can improve the sensitivity and accuracy of prostate cancer diagnosis. This article will review the research on the diagnosis and prognosis of serum miRNA-135, miRNA-141 and PSA for prostate cancer at home and abroad.

关 键 词：前列腺癌 微小RNA miRNA-135 miRNA-141 PSA PSA灰区 

分 类 号：R73[医药卫生—肿瘤]